We can already tinker with human DNA to treat diseases. But being able to edit RNA allows for even more precision – and fewer ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

Development in RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies underpins the growth, as they provide ...

The funding for the gene editing program is in addition to a separate $15 million investment in ReCode that the Foundation ...

Gene therapy for some diseases, including Duchenne muscular dystrophy (DMD), can be tricky because the needed gene is often ...

Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech firm focused on RNA therapies, is poised ...

Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s ...

Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Concurrent DNA and RNA sequencing revealed 15.3% more patients with actionable variants than DNA sequencing alone.